A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS

S. N. Scelsa, D. J L MacGowan, H. Mitsumoto, T. Imperato, A. J. LeValley, M. H. Liu, M. DelBene, Mimi Kim

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

There is some evidence of retroviral infection in ALS. A randomized, double-blind, placebo-controlled trial of indinavir in ALS was performed to assess safety and efficacy trends. Nephrolithiasis and gastrointestinal side effects were frequent with indinavir treatment. Group differences in the rate of decline were not significant between the groups for the ALS Functional Rating Scale (p = 0.36) or for the secondary variables. The toxicity and negative efficacy trends discourage further indinavir trials in ALS.

Original languageEnglish (US)
Pages (from-to)1298-1300
Number of pages3
JournalNeurology
Volume64
Issue number7
StatePublished - Apr 12 2005

Fingerprint

Indinavir
Placebos
Nephrolithiasis
Safety
Infection
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Scelsa, S. N., MacGowan, D. J. L., Mitsumoto, H., Imperato, T., LeValley, A. J., Liu, M. H., ... Kim, M. (2005). A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS. Neurology, 64(7), 1298-1300.

A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS. / Scelsa, S. N.; MacGowan, D. J L; Mitsumoto, H.; Imperato, T.; LeValley, A. J.; Liu, M. H.; DelBene, M.; Kim, Mimi.

In: Neurology, Vol. 64, No. 7, 12.04.2005, p. 1298-1300.

Research output: Contribution to journalArticle

Scelsa, SN, MacGowan, DJL, Mitsumoto, H, Imperato, T, LeValley, AJ, Liu, MH, DelBene, M & Kim, M 2005, 'A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS', Neurology, vol. 64, no. 7, pp. 1298-1300.
Scelsa SN, MacGowan DJL, Mitsumoto H, Imperato T, LeValley AJ, Liu MH et al. A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS. Neurology. 2005 Apr 12;64(7):1298-1300.
Scelsa, S. N. ; MacGowan, D. J L ; Mitsumoto, H. ; Imperato, T. ; LeValley, A. J. ; Liu, M. H. ; DelBene, M. ; Kim, Mimi. / A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS. In: Neurology. 2005 ; Vol. 64, No. 7. pp. 1298-1300.
@article{6f74e13a543e48728053bcad92b0ae95,
title = "A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS",
abstract = "There is some evidence of retroviral infection in ALS. A randomized, double-blind, placebo-controlled trial of indinavir in ALS was performed to assess safety and efficacy trends. Nephrolithiasis and gastrointestinal side effects were frequent with indinavir treatment. Group differences in the rate of decline were not significant between the groups for the ALS Functional Rating Scale (p = 0.36) or for the secondary variables. The toxicity and negative efficacy trends discourage further indinavir trials in ALS.",
author = "Scelsa, {S. N.} and MacGowan, {D. J L} and H. Mitsumoto and T. Imperato and LeValley, {A. J.} and Liu, {M. H.} and M. DelBene and Mimi Kim",
year = "2005",
month = "4",
day = "12",
language = "English (US)",
volume = "64",
pages = "1298--1300",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS

AU - Scelsa, S. N.

AU - MacGowan, D. J L

AU - Mitsumoto, H.

AU - Imperato, T.

AU - LeValley, A. J.

AU - Liu, M. H.

AU - DelBene, M.

AU - Kim, Mimi

PY - 2005/4/12

Y1 - 2005/4/12

N2 - There is some evidence of retroviral infection in ALS. A randomized, double-blind, placebo-controlled trial of indinavir in ALS was performed to assess safety and efficacy trends. Nephrolithiasis and gastrointestinal side effects were frequent with indinavir treatment. Group differences in the rate of decline were not significant between the groups for the ALS Functional Rating Scale (p = 0.36) or for the secondary variables. The toxicity and negative efficacy trends discourage further indinavir trials in ALS.

AB - There is some evidence of retroviral infection in ALS. A randomized, double-blind, placebo-controlled trial of indinavir in ALS was performed to assess safety and efficacy trends. Nephrolithiasis and gastrointestinal side effects were frequent with indinavir treatment. Group differences in the rate of decline were not significant between the groups for the ALS Functional Rating Scale (p = 0.36) or for the secondary variables. The toxicity and negative efficacy trends discourage further indinavir trials in ALS.

UR - http://www.scopus.com/inward/record.url?scp=16844384316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16844384316&partnerID=8YFLogxK

M3 - Article

VL - 64

SP - 1298

EP - 1300

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 7

ER -